96 Tests PN: B112470

Components:

45x Ab-conjugated beads (S4P7 - Human ENA-78 Ab-bead). PN: B112470A. One vial containing 100 µL of anti-Human ENA-78 conjugated to AimPlex Bead S4P7.

25x Biotin-detection Ab (Human ENA-78 Biotin-dAb). PN: B112470B. One vial containing 100 µL of biotinylated anti-Human ENA-78.

Lyophilized Standard Mix-Human Group 6, Panel A, 7-Plex. PN: HG61007. One vial containing lyophilized recombinant 6Ckine, BRAK, BCA-1, CTACK, CCL28, ENA-78, and CXCL16.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Application:Optimal antibody pair and antigen standard for assaying human CXCL5/SCYB5/ENA-78 . Can be multiplexed with other analytes in Human Group 6.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 5 pg/mL

  • Quantitation range:

  • LLOQ: < 10 pg/mL

  • ULOQ: > 2,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 6: Negligible

  • Sample volume: 15 µL/test

Description:

CXCL5 (C-X-C motif chemokine 5), or ENA-78, is a small cytokine belonging to the CXC chemokine family that is also known as epithelial-derived neutrophil-activating peptide 78 (ENA-78). It is produced following stimulation of cells with the inflammatory cytokines interleukin-1 or tumor necrosis factor-alpha. Expression of CXCL5 has also been observed in eosinophils, and can be inhibited with the type II interferon IFN-γ.  This chemokine stimulates the chemotaxis of neutrophils possessing angiogenic properties. CXCL5 has been implicated in connective tissue remodeling. CXCL5 has been also described to regulate neutrophil homeostasis. CXCL5 is well known to have chemotactic and activating functions on neutrophil, mainly during acute inflammatory responses. However, CXCL5 expression is also higher in atherosclerosis (a chronic inflammatory condition) but is not associated with neutrophil infiltration. CXCL5 has a protective role in atherosclerosis by directly controlling macrophage foam cell formation.

References:

  1. Sepuru, K. M.; Poluri, K. M.; Rajarathnam, K. (2014). "Solution Structure of CXCL5 — A Novel Chemokine and Adipokine Implicated in Inflammation and Obesity". PLoS ONE 9 (4): e93228. doi:10.1371/journal.pone.0093228. PMC 3973705. PMID 24695525.

  2. Chang MS, McNinch J, Basu R, Simonet S (Nov 1994). "Cloning and characterization of the human neutrophil-activating peptide (ENA-78) gene". J Biol Chem 269 (41): 25277–82. PMID 7929219.

  3. Dawes JM, Calvo M, Perkins JR, Paterson KJ, Kiesewetter H, Hobbs C, Kaan TK, Orengo C, Bennett DL, McMahon SB (July 2011). "CXCL5 Mediates UVB Irradiation-Induced Pain". Sci Transl Med 3 (90): 90ra60. doi:10.1126/scitranslmed.3002193. PMC 3232447. PMID 21734176. Lay summary – FierceBiotech.

  4. Rousselle A, Qadri F, Leukel L, Yilmaz R, Fontaine JF, Sihn G, Bader M, Ahluwalia A, Duchene J. (2013). "CXCL5 limits macrophage foam cell formation in atherosclerosis.". Journal of Clinical Investigation. 123 (3): 1343–7. doi:10.1172/JCI66580. PMID 23376791.

.